29 completed, 11 terminated, 7 recruiting, 5 not yet recruiting. 60 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 60 | Completed 29, Terminated 11, Recruiting 7, Not yet recruiting 5, Unknown 4, Withdrawn 4 |
Follow Primary Myelofibrosis: new trials by email Literature Review of Primary Myelofibrosis trials Research Report on Primary Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| WELL-MPN: A Digital Lifestyle App for Patients With MPNs WELL-MPN Digital App - Myeloproliferative Neoplasms (MPNs) | Not applicable | Not yet recruiting | Brigham and Women's Hospital | 75 | 2027-01-01 | 2026-09-29 |
| Peri-Transplant Gecacitinib in Patients With Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Peri-Transplant Gecacitinib - Myelofibrosis, Primary Myelofibrosis (PMF) | Not applicable | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 46 | 2026-11-01 | 2026-10-29 |
| ENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic Myeloid Leukemia Participants will take part in a 12-week exercise program that includes aerobic and resistance training, tailored to their individual fitness level and clinical condition. - Myeloproliferative Disease, Polycythemia Vera | Not applicable | Not yet recruiting | Carmen Fava | 25 | 2026-08-01 | 2026-04-09 |
| Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis Gecacitinib - aGVHD Prophylaxis | Not applicable | Not yet recruiting | Nanfang Hospital, Southern Medical University | 40 | 2026-03-01 | 2026-02-27 |
| Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis Low-volume continuous veno-venous haemodialysis with MEX-CD1 use - Myelodysplastic Syndrome, Myelofibrosis | Not applicable | Recruiting | Hospices Civils de Lyon | 13 | 2026-01-06 | 2026-10-13 |
| Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History NGS testing, NGS analysis for mutations in genes involved in familial predisposition to hematological malignancies - Polycythemia Vera, Essential Thrombocythaemia | Not applicable | Not yet recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 496 | 2025-05-21 | 2025-05-15 |
| Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes Monocytes signatures in myeloproliferative neoplasms at diagnosis - Myeloproliferative Neoplasm, Polycythemia Vera | Not applicable | Recruiting | University Hospital, Angers | 70 | 2024-05-29 | 2026-10-29 |
| A Telehealth Advance Care Planning Intervention Telehealth Serious Illness Care Program, Education Control - Myeloid Malignancy, Acute Myeloid Leukemia | Not applicable | Recruiting | University of Rochester | 207 | 2024-05-20 | 2026-09-11 |
| Haplo-HSCT for Myelofibrosis Haploidentical hematopoietic stem cell transplantation - Myelofibrosis | Not applicable | Recruiting | Peking University People's Hospital | 39 | 2024-01-01 | 2026-09-14 |
| A New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C-C Chemokine Receptor 2 Detection. From Flow Cytometry to the Development of Targeted Positron Emission Tomography Molecular Imaging. Pre-clinical Studies and First In-human Proof of Concept Diagnosis of MPN subtypes - Myelofibrosis (MF) | Not applicable | Recruiting | Azienda Ospedaliero-Universitaria di Parma | 265 | 2023-09-05 | 2026-02-18 |
| Clonal Architecture of ASXL1-mutated Myelofibrosis Clonal architecture determination - Myelofibrosis | Not applicable | Recruiting | University Hospital, Angers | 50 | 2023-04-24 | 2026-03-09 |
| Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI) CALR allele burden quantification - Myeloproliferative Neoplasm, Essential Thrombocythemia | Not applicable | Recruiting | University Hospital, Angers | 260 | 2021-10-28 | 2026-03-06 |
| Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study Health Promotion and Education, Medical Device Usage and Evaluation, Quality-of-Life Assessment - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Not applicable | Completed | Ohio State University Comprehensive Cancer Center | 30 | 2021-06-11 | 2026-04-06 |
| Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT Pre-biotic foods/drinks - Multiple Myeloma, Acute Myeloid Leukemia | Not applicable | Completed | University of Virginia | 40 | 2021-02-19 | 2023-01-04 |
| Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms. Non-invasive diagnosis score - Myeloproliferative Disorder, Essential Thrombocythemia | Not applicable | Completed | University Hospital, Angers | 133 | 2019-07-30 | 2024-12-30 |
| The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase USDA Diet, Mediterranean Diet - Myeloproliferative Disorder, Myeloproliferative Syndrome | Not applicable | Completed | University of California, Irvine | 30 | 2018-10-01 | 2020-03-24 |
| Defining the Molecular Risk in Israeli Patients With Secondary Compared to Primary Myelofibrosis Molecular analysis - Myelofibrosis, Primary, Myelofibrosis, Post PV | Not applicable | Unknown | Assaf-Harofeh Medical Center | 222 | 2017-12-10 | 2019-07-05 |
| 18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms Diagnostic (18F-FLT PET/CT) - Essential Thrombocythemia, Primary Myelofibrosis, Fibrotic Stage | Not applicable | Terminated | Hamad Medical Corporation | 3 | 2017-06-11 | 2020-08-11 |
| 18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia Diagnostic (18F-FLT PET/CT) - Essential Thrombocythemia, Primary Myelofibrosis, Fibrotic Stage | Not applicable | Unknown | Hamad Medical Corporation | 21 | 2017-05-07 | 2020-09-29 |
| Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases Fludarabine, Cyclophosphamide, Total Body Irradiation - Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL) | Not applicable | Terminated | Masonic Cancer Center, University of Minnesota | 200 | 2016-12-01 | 2026-05-20 |
Showing 20 of 60. Sign in to see all of them.
Myeloproliferative Disorders (43) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (39) · Leukemia, Myeloid, Acute (37) · Leukemia, Lymphocytic, Chronic, B-Cell (36) · Multiple Myeloma (36) · Hodgkin Disease (35) · Lymphoma, Non-Hodgkin (35) · Lymphoma, Mantle-Cell (34) · Lymphoma, Large B-Cell, Diffuse (33) · Burkitt Lymphoma (32) · Lymphoma, Follicular (32) · Lymphoma, Large-Cell, Immunoblastic (31) · Lymphoma, B-Cell, Marginal Zone (30) · Leukemia, Myeloid, Accelerated Phase (29)
Bone Marrow Diseases (60) · Hematologic Diseases (60) · Hemic and Lymphatic Diseases (60) · Hemorrhagic Disorders (47) · Neoplasms by Histologic Type (43) · Leukemia, Myeloid (42) · Neoplasms (42) · Immune System Diseases (39) · Immunoproliferative Disorders (39) · Lymphatic Diseases (39) · Pathologic Processes (39) · Pathological Conditions, Signs and Symptoms (39) · Chronic Disease (38) · Disease Attributes (38) · Leukemia, Lymphoid (38)
Cyclophosphamide (10) · fludarabine phosphate (9) · Cyclosporine (8) · Peripheral Blood Stem Cell Transplantation (8) · Busulfan (7) · Filgrastim (6) · Mycophenolic Acid (6) · Antilymphocyte Serum (5) · Methotrexate (4) · Psychiatric Rehabilitation (4) · Radiotherapy (4) · Aprepitant (3) · Cord Blood Stem Cell Transplantation (3) · Flow Cytometry (3) · Melphalan (3)
Fred Hutchinson Cancer Center (5) · University Hospital, Angers (4) · City of Hope Medical Center (3) · Masonic Cancer Center, University of Minnesota (3) · Roswell Park Cancer Institute (3) · Wake Forest University Health Sciences (3) · Hamad Medical Corporation (2) · M.D. Anderson Cancer Center (2) · OHSU Knight Cancer Institute (2) · University of California, San Francisco (2) · University of Rochester (2) · Assaf-Harofeh Medical Center (1) · Azienda Ospedaliero-Universitaria di Parma (1) · Barbara Ann Karmanos Cancer Institute (1) · Brigham and Women's Hospital (1)
United States (38) · France (6) · Italy (3) · Israel (2) · Qatar (2) · Belgium (1) · Canada (1) · China (1) · Germany (1) · Slovakia (1) · Switzerland (1) · Turkey (Türkiye) (1)
Charles A. Linker, MD (2) · Paul Martin (2) · Andrew Rezvani (1) · Angela G Fleischman, MD PhD (1) · Ann Woolfrey (1) · Aprille Seidel, PhD (1) · Barbara A. Murphy, MD (1) · Barrie R. Cassileth, PhD (1) · Brady Stein, MD (1) · Carmen Fava (1) · Chi-Joan How (1) · Christopher R. Cogle, MD (1) · Claude Sportes, MD (1) · Claudio Brunstein, MD (1)
PMID 15466923, PMID 18698002, PMID 21719601, PMID 22826273, PMID 23358983, PMID 28817727, PMID 31151984, PMID 32196650, PMID 32519831, PMID 33157979, PMID 36493799, PMID 37877698, PMID 38380328
P30CA033572 (3), P01CA018029 (1), P01HL036444 (1), P30CA015704 (1), P30CA016672 (1), P30CA022453 (1), P30CA060553 (1), P30CA072720 (1), R01AI058148 (1), R01CA107446 (1)